We then used the peptides to stimulate PBMCs from ALS patients and healthy controls in culture (n=33/32, mean disease duration 49 ± 38 months, mean ALSFRS-R 32 ± 11, Supplementary Table 4) and quantified the T-cell response by ELISPOT for IL-5 and IFN-γ (Figure 3A, Supplementary Table 5). The gene discussed is IL5; the disease is amyotrophic lateral sclerosis.